Ana Lúcia Beltrame
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Lúcia Beltrame has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Edmund C. Baracat
Department of Obstetrics and Gynecology, School of Medicine, University of São Paulo (USP), São Paulo, Brazil
1 shared publication - Eduardo Leme Alves da Motta
Huntington Medicina Reprodutiva—Eugin Group, São Paulo 04501-000, SP, Brazil
1 shared publication José Maria Soares Júnior
Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil
1 shared publicationPaulo Serafini
Department of Obstetrics and Gynecology, School of Medicine, University of São Paulo (USP), São Paulo, Brazil
1 shared publication
Latest Publications
- 20 November 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (3) , 201-204
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome inin vitrofertilization patients: a pilot study
The aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two groups and were administered daily oral capsules for 14 days, starting on the day of human chorionic gonadotropin (hCG) administration. Group A received 2.0 mg of folic acid, whereas Group B was given 2.5 mg of bromocriptine. Physical exams, pelvic ultrasounds and laboratory evaluations were performed on the day of hCG administration and again 7 days later. No differences in ovarian hyperstimulation syndrome, urine volume, creatinine clearance, urine sodium concentration or serum VEGF levels were found between the two groups. Thus, these results indicate that bromocriptine does not affect blood levels of VEGF, kidney function or the incidence of ovarian hyperstimulation syndrome in high-risk patients subjected to in vitro fertilization.
- 20 November 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (3) , 201-204
The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome inin vitrofertilization patients: a pilot study
The aim of this study was to evaluate the effects of bromocriptine on vascular endothelial growth factor (VEGF) levels in serum, kidney function and ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Twenty-eight women were randomly divided into two groups and were administered daily oral capsules for 14 days, starting on the day of human chorionic gonadotropin (hCG) administration. Group A received 2.0 mg of folic acid, whereas Group B was given 2.5 mg of bromocriptine. Physical exams, pelvic ultrasounds and laboratory evaluations were performed on the day of hCG administration and again 7 days later. No differences in ovarian hyperstimulation syndrome, urine volume, creatinine clearance, urine sodium concentration or serum VEGF levels were found between the two groups. Thus, these results indicate that bromocriptine does not affect blood levels of VEGF, kidney function or the incidence of ovarian hyperstimulation syndrome in high-risk patients subjected to in vitro fertilization.